Repaglinide
Links shared publicly online about this topic
Sun Pharmaceutical Industries Europe B.V. Withdraws Its Marketing Authorisation Application For Repaglinide SUN (repaglinide)
medicalnewstoday.com — “The European Medicines Agency has been formally notified by Sun Pharmaceutical Industries B.V. of its decision to withdraw its application for a centralised marketing authorisation for the medicin” View full resource at medicalnewstoday.com
Most Recently Shared on March 26, 2010 at 2:07 pm By:
MNT Drug Approvals Health News
Sun Pharmaceutical Industries Europe B.V. Withdraws Its Marketing Authorisation Application For Repaglinide SUN (repag... http://mnt.to/3zty
PRANDIMET 1mg/500mg (Metformin, Repaglinide) drug information from MPR
empr.com — “PRANDIMET 1mg/500mg (Metformin, Repaglinide) drug information for Diabetes mellitus~hyperglycemic agents from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.” View full resource at empr.com
Most Recently Shared on November 5, 2010 at 4:19 am By:
MPR News: PRANDIMET 1mg/500mg: Contraindications: concomitant gemfibrozil. http://bit.ly/cHGW6z
PRANDIMET 2mg/500mg (Metformin, Repaglinide) drug information from MPR
empr.com — “PRANDIMET 2mg/500mg (Metformin, Repaglinide) drug information for Diabetes mellitus~hyperglycemic agents from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.” View full resource at empr.com
Most Recently Shared on November 5, 2010 at 4:19 am By:
MPR News: PRANDIMET 2mg/500mg: Contraindications: concomitant gemfibrozil. http://bit.ly/cjYQtQ
Symptomatic Hypoglycemia Associated with Trimethoprim/Sulfamethoxazole and Repaglinide in a Diabetic Patient (April) -- Roustit et al., 10.1345/aph.1M597 -- The Annals of Pharmacotherapy
theannals.com — “Symptomatic Hypoglycemia Associated with Trimethoprim/Sulfamethoxazole and Repaglinide in a Diabetic Patient (April) -- Roustit et al., 10.1345/aph.1M597 -- The Annals of Pharmacotherapy” View full resource at theannals.com
Most Recently Shared on March 3, 2010 at 3:27 am By:
Symptomatic Hypoglycemia Associated with Trimethoprim/Sulfamethoxazole and Repaglinide in a Diabetic Patient (Apri... http://bit.ly/c77EI6
Endocrinology Article | Lipids
mdlinx.com — “Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in” View full resource at mdlinx.com
Most Recently Shared on January 25, 2011 at 5:14 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profile... http://bit.ly/fGD4E6 #endo
Danish analysis finds higher risk for CV death with certain glucose-lowering medications
endocrinetoday.com — “American Diabetes Association's 69th Scientific Sessions A nationwide Danish study showed that gliclazide, repaglinide and acarbose had sim” View full resource at endocrinetoday.com
Most Recently Shared on June 7, 2009 at 2:25 pm By:
ADA: Danish analysis finds higher risk for CV death with certain glucose-lowering medications ... http://tinyurl.com/pjk3h8
Vildagliptin preserved protective effects of ischemic preconditioning in diabetes, CAD
endocrinetoday.com — “ADA 70th Scientific Sessions ORLANDO — Compared with repaglinide, vildagliptin did not affect the protective mechanism of myocardial isc” View full resource at endocrinetoday.com
Most Recently Shared on June 28, 2010 at 3:27 pm By:
Findings suggest vildagliptin preserved protective effects of ischemic preconditioning in #diabetes, CAD #ADA2010 http://ow.ly/24cXt
Meglitinides for Diabetes - Diabetes Medication - Meglitinides
diabetes.about.com — “Meglitinides are oral medications used in the treatment of type 2 diabetes. Medications in this class include Prandin (repaglinide) and Starlix (nateglinide).” View full resource at diabetes.about.com
Most Recently Shared on July 24, 2010 at 6:45 pm By:
Meglitinides: Meglitinides are oral medications used in the treatment of type 2 diabetes. Medications in this clas... http://bit.ly/czPHiE
3 diabetes drugs beat rivals in preventing heart disease - Related Stories - DiabetesPro SmartBrief
smartbrief.com — “Diabetes drugs metformin, gliclazide and repaglinide proved more effective than other treatments in lowering the risks of cardiovascular disease and death, according to a study of more than 100,000 Danish people older than 20. Glimepiride, glibenclamide, glipizide and tolbutamide were linked to a h--” View full resource at smartbrief.com
Most Recently Shared on April 8, 2011 at 5:56 pm By:
Margarita Ochoa-Maya, MD, CDE Physician, Doctor, Internist, and Endocrinologist
3 diabetes drugs beat rivals in preventing heart disease http://sbne.ws/r/7d68
3 diabetes drugs beat rivals in preventing heart disease - DiabetesPro SmartBrief
smartbrief.com — “Diabetes drugs metformin, gliclazide and repaglinide proved more effective than other treatments in lowering the risks of cardiovascular disease and death, according to a study of more than 100,000 Danish people older than 20. Glimepiride, glibenclamide, glipizide and tolbutamide were linked to a h--” View full resource at smartbrief.com
Most Recently Shared on April 13, 2011 at 12:15 am By:
Here's a note to brighten your day: good news about 3 common medications. It's so nice to hear that something has... http://fb.me/SEx66HAZ
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
MNT Drug Approvals
The latest regulatory affairs / drug approvals news published daily. Articles from research centers, universities and prestigious journals.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
